This launch will benefit company to sustain in long period of time
GLP-1 receptor agonists include widely used medications such as semaglutide, liraglutide, and dulaglutide
Payers argue that behavioral and dietary interventions should be exhausted first, despite clinical evidence showing tirzepatide produces 21% average body weight reduction in trials
It seems to reduce body fat in several different ways, including increasing GLP-1 production in the body
For these patients, the question is "will I tolerate this long enough to see results?" Problem 2: Injection-site reactions
Patients should use a new needle for each injection, as reusing needles can cause tissue trauma, increase infection risk, and potentially contribute to injection site reactions